Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Silo Pharma, Inc.

< Previous 1 2 3 Next >
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma to Present at Psychedelic Drug Development Conference
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Expansion of Intellectual Property Portfolio
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Stock Repurchase Program
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO SILOD
Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO SILOD
Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO SILOD
Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO SILOD
Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO SILOD
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.